VNTA Stock Overview
A development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ventana Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0004 |
| 52 Week High | US$0.0032 |
| 52 Week Low | US$0.0003 |
| Beta | 0 |
| 11 Month Change | -61.90% |
| 3 Month Change | -84.56% |
| 1 Year Change | -80.95% |
| 33 Year Change | -87.88% |
| 5 Year Change | -95.92% |
| Change since IPO | 266.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| VNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -81.0% | 15.6% | 30.7% |
Return vs Industry: VNTA underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: VNTA underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| VNTA volatility | |
|---|---|
| VNTA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VNTA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VNTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Janne Christensen | n/a |
Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. The company focuses in the areas of anti-obesity and related illnesses. The company holds rights for the formula for a medicament containing chewing gum with a composition of the extract of hoodia gordonii and 2-hydroxyoleic acid for the treatment of obesity, hypertension, and other metabolic disorders.
Ventana Biotech, Inc. Fundamentals Summary
| VNTA fundamental statistics | |
|---|---|
| Market cap | US$22.03k |
| Earnings (TTM) | -US$47.08k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VNTA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$260.00 |
| Gross Profit | -US$260.00 |
| Other Expenses | US$46.82k |
| Earnings | -US$47.08k |
Last Reported Earnings
Apr 30, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VNTA perform over the long term?
See historical performance and comparison